Handelsavisen
prelaunch
EP
EPSM.O NASDAQ Food & Drug Retailing

Epsium Enterprise Ltd

$1,36
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
18,3M USD
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Epsium Enterprise Ltd operates in the Food Retail & Distribution industry, primarily generating revenue through the sale of food and drug products to consumers.

Business. Epsium Enterprise Ltd (EPSM.O) is a food and drug retailer engaged in the retailing and distribution of food and drug products. The company is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %
SectorConsumer Staples
Industry groupFood & Drug Retailing
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning EPSM.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to EPSM.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Epsium Enterprise Ltd (EPSM.O) is a food and drug retailer engaged in the retailing and distribution of food and drug products. The company is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorConsumer Staples
    Industry groupFood & Drug Retailing
    AI synthesis
    GENERATED

    Epsium Enterprise Ltd maintains a strong liquidity position, with cash and equivalents amounting to $1,978,730, representing 17.2% of total equity. The company's enterprise value to revenue ratio of 3.34 suggests a relatively low valuation compared to revenue, and its debt-to-equity ratio of 0.0 indicates no leverage. This capital structure supports operational flexibility and reduces financial risk.

    Profitability metrics show mixed performance. The company reported negative operating cash flow of $2,379,180, which may signal operational inefficiencies or high working capital requirements. However, the absence of debt and the high cash reserves mitigate some of the risks associated with negative cash flow. The company's return on invested capital (ROIC) and other profitability metrics are not disclosed, but the lack of leverage suggests a conservative capital allocation strategy.

    Geographically and segment-wise, Epsium Enterprise Ltd's revenue concentration is not disclosed in the available data. The company operates in the Food & Drug Retailing industry, which is typically characterized by stable demand and high customer retention. However, without segment-specific revenue breakdowns, it is difficult to assess the company's exposure to different product lines or geographic regions.

    The company's growth trajectory is not clearly defined in the available data. No specific revenue growth rates or future projections are provided. The capital expenditure of $4,160 is minimal, suggesting limited investment in new assets or expansion. This could indicate a mature business with limited growth opportunities or a focus on maintaining existing operations.

    Risk factors for Epsium Enterprise Ltd are minimal in the short term. The company has no immediate liquidity or dilution flags, and its low debt-to-equity ratio reduces financial risk. However, the negative operating cash flow is a concern that may require further investigation. The company has not issued additional shares recently, and there is no indication of near-term dilution pressure.

    Recent events and filings do not show any material changes in the company's operations or financial position. The company's financial statements and disclosures are consistent with a stable but low-growth business model. No significant regulatory or geopolitical risks are highlighted in the available data.

    Key takeaways
    • Epsium Enterprise Ltd has a strong liquidity position with no leverage, reducing financial risk.
    • The company's negative operating cash flow is a red flag that may require further analysis.
    • The low enterprise value to revenue ratio suggests the company is undervalued relative to its revenue.
    • There are no immediate liquidity or dilution risks, and the company has not issued additional shares recently.
    • The company's growth trajectory is unclear, and there is limited investment in new assets or expansion.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1,36
    Market cap
    $19.1M
    Enterprise value
    $17.1M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    $2.0M
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    -0.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYConsumer Non-CyclicalsIndustryFood & Drug Retailing63,3B node revenueFMX 59,2%CASY 25,2%TBBB 7,2%DIT 4,5%VLGEA 3,7%PETS 0,3%AGCC 0,0%EPSM 0,0%
    Source: company disclosures · own-taxonomy revenue-covered setEPSM 0,0% · rank #8 of 9

    Business relationships

    Business relationships3 disclosed relationships · 2 types · extracted from filings & disclosures
    Customers2
    ANON:CUST:EPSM.O:P14.2ANON:CUST:EPSM.O:P14.2Customer88%Source ↗
    ANON:CUST:EPSM.O:P28ANON:CUST:EPSM.O:P28Customer88%Source ↗
    Suppliers1
    ANON:SUPP:EPSM.O:P17.83ANON:SUPP:EPSM.O:P17.83Supplier88%Source ↗

    Supply chain

    Vendors → EPSM ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSEPSMEPSMEpsium Enterprise Ltd3 entitiesANON:SUPP:EPSM.O:P17.8ANON:CUST:EPSM.O:P14.2ANON:CUST:EPSM.O:P28
    3 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-07-04

    Peer comparison

    Peer comparison7 peers · vs EPSM · multiples and returns
    FM
    FMX
    FMX
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    CA
    CASY
    Casey's General Stores, Inc.
    $860,37
    32,1B USD
    P/E
    42,2x
    vs self
    Div yield
    vs self
    ROE
    18,1 %
    vs self
    TB
    TBBB
    Bbb Foods Inc
    $36,74
    4,3B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -68,8 %
    vs self
    DI
    DIT
    Amcon Distributing Co
    $62,60
    58,1M USD
    P/E
    vs self
    Div yield
    1,2 %
    vs self
    ROE
    -1,2 %
    vs self
    VL
    VLGEA
    VILLAGE SUPER MARKET, INC.
    $43,90
    647,6M USD
    P/E
    12,2x
    vs self
    Div yield
    2,3 %
    vs self
    ROE
    11,5 %
    vs self
    PE
    PETS
    Petmed Express Inc
    $1,98
    42,4M USD
    P/E
    vs self
    Div yield
    0,0 %
    vs self
    ROE
    -5,2 %
    vs self
    AG
    AGCC
    Agencia Comercial Spirits Lt
    $15,00
    341,8M USD
    P/E
    512,6x
    vs self
    Div yield
    vs self
    ROE
    41,0 %
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Capex / Rev-0,1 %Above median
    D/E0,00Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    Source documents
    • Epsium Enterprise Ltd Market data — financials · 2026-05-27

    Ownership & reference

    Top holders

    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    — missing data

    Short positioning

    71.5Kshares short+6.7% vs prior
    1days to cover
    46.8%short of daily vol
    3.4Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    EPSM.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    EPSMANON:CUSANON:CUSANON:SUPFood & Drug Re
    This companySectorCustomersSuppliers

    Evidence & claims

    From filings & derived data
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 25.1%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -24.8%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.16xDerived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -59.1%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -466.8%Derived (calculated)
    • Net margin (FY 2025-12-31): -29.3%Derived (calculated)
    • Gross margin (FY 2025-12-31): 14.7%Derived (calculated)
    • Return on equity (FY 2025-12-31): -13.0%Derived (calculated)
    • Return on assets (FY 2025-12-31): -11.3%Derived (calculated)
    • Current ratio (FY 2025-12-31): 7.35xDerived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -70.8%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -644.9%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): -53.0%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -60.0%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -95.0%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 41.5%Derived (calculated)
    • Gross profit (annual): USD 753.77KSEC XBRL filing
    • Revenue (annual): USD 5.12MSEC XBRL filing
    • Net income (annual): USD -1.5MSEC XBRL filing
    • Total assets (annual): USD 13.3MSEC XBRL filing
    • Capex (annual): USD 4.16KSEC XBRL filing
    • Current liabilities (annual): USD 1.77MSEC XBRL filing
    • Total liabilities (annual): USD 1.82MSEC XBRL filing
    • Pre-tax income (annual): USD -1.5MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-04-29FILINGANNUAL REPORT →
    2025-04-30FILINGANNUAL REPORT →
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage